trending Market Intelligence /marketintelligence/en/news-insights/trending/oju85okerax8cy6nfd38bq2 content esgSubNav
In This List

Heron Therapeutics stocks rise on positive late-stage trial results

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Heron Therapeutics stocks rise on positive late-stage trial results

Heron Therapeutics Inc. said its treatment HTX-011 was better at reducing post-surgery pain when compared to the current standard-of-care local anesthetic.

HTX-011 was being evaluated against bupivacaine — an anesthetic sold under multiple brand names, including Marcaine — in two separate phase 3 trials known as study 301/Epoch1 and study 302/Epoch2.

The drug was also evaluated against a placebo.

Study 301, which involved 412 patients who had undergone a bunionectomy surgery, resulted in a 27% reduction in pain intensity when comparing HTX-011 to placebo and an 18% reduction when compared to bupivacaine.

Over 72 hours after surgery, patients receiving HTX-011 consumed 37% fewer opioids than placebo and 25% fewer opioids than patients receiving bupivacaine.

Meanwhile, 29% of patients receiving HTX-011 required no opioid medication for 72 hours post-surgery, compared to only 2% receiving placebo and 11% receiving bupivacaine.

Study 302, which enrolled 418 subjects who had undergone a hernia repair surgery, resulted in a 23% reduction in the intensity of pain when compared to placebo and a 21% reduction in pain when compared to bupivacaine.

Over 72 hours after surgery, patients receiving HTX-011 consumed 38% fewer opioids than placebo patients and 25% fewer opioids than patients receiving bupivacaine.

Furthermore, 51% of patients receiving HTX-011 required no opioid medication for 72 hours post-surgery compared to only 22% receiving placebo and 40% receiving bupivacaine.

The San Diego-based company's stock was up 26.26% on the news to $27.15 per share as of 11:44 a.m. ET on March 19.